Cellular assays as portals to seven-transmembrane receptor-based drug discovery

Terry P. Kenakin

doi:10.1038/nrd2838

journal article Jul 17, 2009

Cellular assays as portals to seven-transmembrane receptor-based drug discovery

Terry P. Kenakin

Nature Reviews Drug Discovery Vol. 8 No. 8 pp. 617-626 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/nrd2838

Topics

No keywords indexed for this article. Browse by subject →

References

99

[1]

Black, J. W., Duncan, W. A. & Shanks, R. G. Comparison of some properties of pronethalol and propranolol. Br. J. Pharmacol. Chemo. 25, 577–591 (1965). 10.1111/j.1476-5381.1965.tb01782.x

[2]

β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors

Mounia Azzi, Pascale G. Charest, Stephane Angers et al.

Proceedings of the National Academy of Sciences 2003 10.1073/pnas.1936664100

[3]

Costa, T. & Herz, A. Antagonists with negative intrinsic activity at δ-opioid receptors coupled to GTP-binding proteins. Proc. Natl Acad. Sci. 86, 7321–7325 (1989). 10.1073/pnas.86.19.7321

[4]

Kenakin, T. P. Efficacy as a vector: the prevalence and paucity of inverse agonism. Mol. Pharmacol. 65, 2–11 (2004). 10.1124/mol.65.1.2

[5]

Metra, M., Cas, L. D., di Lenarda, A. & Poole-Wilson, P. Beta-blockers in hear failure: Are pharmacological differences clinically important? Heart Fail. Rev. 9, 123–130 (2005). 10.1023/b:hrev.0000046367.99002.a4

[6]

Wisler, J. W. et al. A unique mechanism of β-blocker action: carvedilol stimulates b-arrestin signaling. Proc. Natl Acad. Sci. USA 104, 16657–16662 (2007). 10.1073/pnas.0707936104

[7]

Galandrin, S. & Bouvier, M. Distinct signaling profiles of β1 and β2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol. Pharmacol. 70, 1575–1584 (2006). 10.1124/mol.106.026716

[8]

Holmstedt, B. & Liljestrand, G. Readings in Pharmacology (Raven Press, New York, 1981).

[9]

Paton, W. D. M. On becoming a pharmacologist. Ann. Rev. Pharmacol. Toxicol. 26, 1–22 (1986). 10.1146/annurev.pa.26.040186.000245

[10]

Vane, J. R. The second Gaddum memorial lecture: The release and fate of vaso-active hormones in the circulation. Br. J. Pharmacol. 35, 209–242 (1969). 10.1111/j.1476-5381.1969.tb07982.x

[11]

Parsons, M. E. & Ganellin, C. R. Histamine and its receptors. Br. J. Pharmacol. 147, S127–S135 (2006). 10.1038/sj.bjp.0706440

[12]

Kenakin, T. P. The Pharmacologic Analysis of Drug Receptor Interaction 3rd edn 1–491 (Lippincott-Raven, New York, 1987).

[13]

Self-cancellation of drug properties as a mode of organ selectivity: the antimuscarinic effects of ambenonium.

T P Kenakin, D Beek

The Journal of Pharmacology and Experimental Thera... 1985 10.1016/s0022-3565(25)20887-4

[14]

CPCCOEt, a Noncompetitive Metabotropic Glutamate Receptor 1 Antagonist, Inhibits Receptor Signaling Without Affecting Glutamate Binding

Stephane Litschig, Fabrizio Gasparini, Doris Rueegg et al.

Molecular Pharmacology 1999 10.1016/s0026-895x(24)12169-4

[15]

The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor

Christian Watson, Stephen Jenkinson, Wieslaw Kazmierski et al.

Molecular Pharmacology 2005 10.1124/mol.104.008565

[16]

Maeda, K. et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 78, 8654–8662 (2004). 10.1128/jvi.78.16.8654-8662.2004

[17]

Kenakin, T. P. G-protein coupled receptors as allosteric machines. Recept. Channels 10, 51–60 (2004). 10.1080/10606820490464316

[18]

Hall, D. A. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol. 58, 1412–1423 (2000). 10.1124/mol.58.6.1412

[19]

Williams, M. in Comprehensive Medicinal Chemistry 2nd edn (ed. Moos, W. H) 265–288 (Elsevier, Oxford, 2007).

[20]

Hay, D. L. Christopoulos, G. Christopoulos, A. & Sexton, P. M. Amylin receptors: molecular composition and pharmacology. Biochem. Soc. Trans. 32, 865–867 (2004). 10.1042/bst0320865

[21]

Udawela, M. et al. Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors. Mol. Pharm. 69, 1984–1989 (2006). 10.1124/mol.105.021915

[22]

Hay, D. L., Poyner, D. R. & Sexton, P. M. GPCR modulation by RAMPS. Pharmacol. Ther. 109, 173–197 (2006). 10.1016/j.pharmthera.2005.06.015

[23]

Smart, D., Coppell, A., Rossant, C., Hall, M. & McKnight, A. T. Characterization using microphysiometry of CRF receptor pharmacology. Eur. J. Pharmacol. 379, 229–235 (1999). 10.1016/s0014-2999(99)00506-3

[24]

The Energy Landscapes and Motions of Proteins

Hans Frauenfelder, Stephen G. Sligar, Peter G. Wolynes

Science 1991 10.1126/science.1749933

[25]

A Statistical Thermodynamic Model of the Protein Ensemble

Vincent J. Hilser, Bertrand García-Moreno E., Terrence G. Oas et al.

Chemical Reviews 2006 10.1021/cr040423+

[26]

Hilser, V. J. & Thompson, E. B. Intrinsic disorder as a mechanism to optimize allosteric coupling in proteins. Proc. Natl Acad. Sci. USA 104, 8311–8315 (2007). 10.1073/pnas.0700329104

[27]

Intrinsic Disorder in Transcription Factors

Jiangang Liu, Narayanan B. Perumal, Christopher J. Oldfield et al.

Biochemistry 2006 10.1021/bi0602718

[28]

Onaran, H. O. & Costa, T. Agonist efficacy and allosteric models of receptor action. Ann. N.Y. Acad. Sci. 812, 98–115 (1997). 10.1111/j.1749-6632.1997.tb48150.x

[29]

Onaran, H. O., Scheer, A., Cotecchia, S. & Costa, T. in The Pharmacology of Functional, Biochemical, and Recombinant Systems Handbook of Experimental Pharmacology Vol. 148 (eds Kenakin, T. P. & Angus, J.A.) 217–280 (Springer, Heidelberg, 2000).

[30]

Kenakin, T. P. & Onaran, O. The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol. Sci. 23, 275–280 (2002). 10.1016/s0165-6147(02)02036-9

[31]

Kenakin, T. P. Efficacy at G protein-coupled receptors. Nature Rev. Drug Discov. 1, 103–109 (2002). 10.1038/nrd722

[32]

Burgen, A. S. V. Conformational changes and drug action. Fed. Proc. 40, 2723–2728 (1981).

[33]

Gether, U. et al. Fluorescent labeling of purified β2-adrenergic receptor: evidence for ligand specific conformational changes. J. Biol. Chem. 270, 28268–28275 (1995). 10.1074/jbc.270.47.28268

[34]

Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic Receptor

Pejman Ghanouni, Zygmunt Gryczynski, Jacqueline J. Steenhuis et al.

Journal of Biological Chemistry 2001 10.1074/jbc.c100162200

[35]

Hruby, V. J. & Tollin, G. Plasmon-waveguide resonance (PWR) spectroscopy for directly viewing rates of GPCR/G-protein interactions and quantifying affinities. Curr. Opin. Pharmacol. 7, 507–514 (2007). 10.1016/j.coph.2007.08.001

[36]

Palanche, T. et al. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J. Biol. Chem. 276, 34853–34861 (2001). 10.1074/jbc.m104363200

[37]

Sequential Binding of Agonists to the β2 Adrenoceptor

Gayathri Swaminath, Yang Xiang, Tae Weon Lee et al.

Journal of Biological Chemistry 2004 10.1074/jbc.m310888200

[38]

Transduction of Receptor Signals by ß-Arrestins

Robert J. Lefkowitz, Sudha K. Shenoy

Science 2005 10.1126/science.1109237

[39]

Luttrell, L. M. Composition and function of G protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity. J. Mol. Neurosci. 26, 253–263 (2005). 10.1385/jmn:26:2-3:253

[40]

Wang, Q. & Limbird, L. E. Regulation of alpha2AR trafficking and signaling by interacting proteins. Biochem. Pharmacol. 73, 1135–1145 (2007). 10.1016/j.bcp.2006.12.024

[41]

Brady, A. E. & Limbird, L. E. G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell. Signal. 14, 297–309 (2002). 10.1016/s0898-6568(01)00239-x

[42]

Antagonist-Stimulated Internalization of the G Protein-Coupled Cholecystokinin Receptor

B.F. Roettger, D. Ghanekar, R. Rao et al.

Molecular Pharmacology 1997 10.1016/s0026-895x(24)13474-8

[43]

Ligand-selective receptor conformations revisited: the promise and the problem

Terry Kenakin

Trends in Pharmacological Sciences 2003 10.1016/s0165-6147(03)00167-6

[44]

Gray, J. A. & Roth, B. L. Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists. Brain Res. Bulletin 56, 441–451 (2001). 10.1016/s0361-9230(01)00623-2

[45]

Kenakin, T. P. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nature Rev. Drug Discov. 4, 919–927 (2005). 10.1038/nrd1875

[46]

Kunkel, E. J. et al. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMap analysis in complex human primary cell-based models. Assay Drug. Dev. Technol. 2, 431–441 (2004). 10.1089/adt.2004.2.431

[47]

Stephenson, R. P. A modification of receptor theory. Br. J. Pharmacol. 11, 379–393 1956 (1956).

[48]

Kenakin, T. P. Agonist-receptor efficacy II: agonist-trafficking of receptor signals. Trends Pharmacol. Sci. 16, 232–238 (1995). 10.1016/s0165-6147(00)89032-x

[49]

Kenakin, T. P. Efficacy at G protein coupled receptors. Ann. Rev. Pharmacol. Toxicol. 42, 349–379 (2002). 10.1146/annurev.pharmtox.42.091401.113012

[50]

Violin, J. D. & Lefkowitz, R. J. β-Arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 28, 416–422 (2007). 10.1016/j.tips.2007.06.006

Showing 50 of 99 references

Metrics

141

Citations

99

References

Details

Published: Jul 17, 2009
Vol/Issue: 8(8)
Pages: 617-626
License: View

Authors

T

Terry P. Kenakin

Cite This Article

Terry P. Kenakin (2009). Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nature Reviews Drug Discovery, 8(8), 617-626. https://doi.org/10.1038/nrd2838

Cellular assays as portals to seven-transmembrane receptor-based drug discovery

You May Also Like